Medpace Holdings, Inc. (MEDP)

Market Cap	10.11B
Revenue (ttm)	2.07B
Net Income (ttm)	365.57M
Shares Out	31.01M
EPS (ttm)	11.42
PE Ratio	28.55
Forward PE	26.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	375,973
Open	313.62
Previous Close	314.96
Day's Range	313.62 - 327.89
52-Week Range	268.80 - 459.77
Beta	1.37
Analysts	Buy
Price Target	388.44 (+19.12%)
Earnings Date	Oct 21, 2024

About MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 5,900
• Stock Exchange: NASDAQ
• Ticker Symbol: MEDP
• Website: https://www.medpace.com

Financial Performance

In 2023, Medpace Holdings's revenue was $1.89 billion, an increase of 29.17% compared to the previous year's $1.46 billion. Earnings were $282.62 million, an increase of 15.26%.

Analyst Forecast

According to 10 analysts, the average rating for MEDP stock is "Buy." The 12-month stock price forecast is $388.44, which is an increase of 19.12% from the latest price.

Price Target

$388.44

(19.12% upside)

Analyst Consensus: Buy